Institut National De La Sante Et De La Recherche Medicale

Pascale Giraudon

Marie-Françoise Belin

Armand Bensussan

Laurence Boumsell

Jean-Christophe Antoine

Jérôme Honnorat

Christophe Malcus

Pierre Colas

The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.

Use of anti-CD100 antibodies for the treatment of inflammatory disorders affecting the central or peripheral nervous system

The invention concerns the use of at least a protein of the CRMP family, a polypeptide fragment or an active biological derivative thereof, a nucleotide sequence or sequence fragment coding for said protein, an antisense sequence capable of being specifically hybridized with a sequence with nucleotide-type encoding of said protein or an antibody directed against said protein for producing a medicine for treating diseases related to a dysfunction of the immune system. The invention also concerns a method for diagnosing an autoimmune pathology which consists in measuring the expression of a CRMP protein in the lymphocytes.

Use of a protein of the CRMP family for treating diseases related to the immune system

Growing community of inventors

Lyons, France

Pascale Giraudon